Grasse, France

Jerôme Aubert

USPTO Granted Patents = 12 

 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 53(Granted Patents)


Company Filing History:


Years Active: 2009-2018

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: Jerôme Aubert: Innovator in Chemokine-Mediated Disease Treatment

Introduction

Jerôme Aubert is a notable inventor based in Grasse, France. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of chemokine-mediated diseases. With a total of six patents to his name, Aubert's work is recognized for its innovative approach to medical treatments.

Latest Patents

Aubert's latest patents include the development of disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds. These compounds are designed for use in the treatment of chemokine-mediated diseases. The methods for preparing these compounds are detailed in his patents, which also describe pharmaceutical compositions that incorporate them. Additionally, he has developed compounds aimed at treating chemokine-mediated pathologies, further showcasing his expertise in this area.

Career Highlights

Jerôme Aubert is currently associated with Galderma Research & Development, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing treatments that target specific medical conditions, demonstrating his commitment to improving patient outcomes.

Collaborations

Aubert collaborates with esteemed colleagues such as Branislav Musicki and Patricia Rossio. Their combined expertise contributes to the success of their projects and enhances the research environment at Galderma.

Conclusion

Jerôme Aubert's contributions to the field of pharmaceuticals, particularly in the treatment of chemokine-mediated diseases, highlight his role as an influential inventor. His innovative patents and collaborations reflect his dedication to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…